assays

Are you ready for the grand finale of our Year in Review Recording? 

The final episode of 2022 is here, and it's one for the books! We've explored the cutting-edge innovations and technologies shaping the future of the biotech industry with some of the most brilliant minds in the field. From Kurt Höller of EIT Health, to Albert Missbichler from Fianostics, Caroline Heil from the new meat company, Mauricio Agudelo and Lina Toro from Bialtec, Kimberly Cornfield from the UCL, Collin Ewald from ETH Zurich, and Guido Gualdoni from G.ST Antiviral, we've had some truly enlightening conversations. 

But we saved the best for last! 

Get ready for an exclusive interview with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions that is revolutionizing the way we study molecular interactions and protein stability. Don't miss out on this one-of-a-kind episode. 

Tune in now!

 This cutting-edge biotech company is revolutionizing how we study molecular interactions and protein stability. They're doing it with a track record of over 1400 successfully completed tasks in research projects with over 350 customers in the last 11 years.

In this episode, you'll get an inside look at the driving force behind 2bind and the expert knowledge that sets them apart in the biophysics field. From breakthrough moments to industry trends, you'll gain a deeper understanding of the future of biotech and the role that companies like 2bind will play in shaping it.

But that's not all! You'll also hear from Dr. Schubert about the company's partnerships with leading device producers and how they navigate the digital world to stay ahead of the curve. Plus, you'll get insight into the supply chain challenges that 2bind faced in the last years and how they overcame them.

Don't miss out on this opportunity to learn from the best in the business! Tune in to our latest podcast episode and join the conversation on the future of biotech.

Trust us; this episode is a must-listen for anyone in the biotech industry or anyone passionate about innovation and the future of medicine. It's packed with valuable insights and information you won't miss.

💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Check out our partners: https://linktr.ee/lsg2
Watch on Youtube
Thomas Schubert
Christian Soschner

⏰  Timestamps:
00:00) Introduction
(02:00) Unveiling the mastermind behind 2bind, Dr. Thomas Schubert 
(04:05) Insider tips for starting your own biotech company
(07:36) A glimpse into the future: 2022 for 2bind's CEO 
(10:40) Navigating the digital world: Pros and cons of technology in biotech 
(14:16) Overcoming obstacles: A look at 2bind's supply chain challenges 
(18:21) Game-changing developments in biophysics for 2022 
(19:53) What's next for the industry? A preview of biophysics trends to come 
(23:19) Peeking into the crystal ball: 2bind

Join Christian Soschner for expert coaching.
50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.

Join the Podcast Newsletter: Link

This week we welcome the President of BioSignal2, Inc Roger Bossé, Ph.D., to discuss using technologies based on Lanthanides emission (TRF, TR-FRET, LOCI) to perform ultrasensitive assays. Bosse is a leading expert on a wide range of detection technologies and applications that work in conjunction with microplate readers.

Key Learning Points:

• What lanthanides are and how they can be used for assays
• The type of research lanthanide-based assays are ideal for
• What researchers need to know to use lanthanide-based assays for research
• The future advancement of lanthanide-based assays technology

Learn more about our BioSignal2 Inc. by visiting: http://www.biosignal2.com/

About Roger Bosse:
Bosse was the key individual that commercialized and developed the unique screening reagent platform “AlphaScreen” at PerkinElmer. He then expanded its breadth and scope to cover many applications in drug discovery and life sciences in general. Roger is highly skilled at assay design and development for early drug discovery efforts and has extensive cell signaling expertise. 

Our Sponsor for this Episode
TheWell Bioscience – developer of VitroGel, a next-generation xeno-free 3D extracellular matrix (ECM), enables scientists to shift from 2D to 3D cell culture and help drive innovations for precision medicine, cell therapy and biomanufacturing by getting faster and more accurate data than animal-based systems.

Learn more about TheWell Bioscience by visiting:
www.thewellbio.com

Stay connected with SLAS

• Online at www.slas.org
• Facebook
• Twitter @SLAS_Org
• LinkedIn
• Instagram @slas_org
• YouTube

About SLAS
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.  For more information about SLAS, visit www.slas.org.

SLAS publishes two peer-reviewed and MEDLINE-indexed scientific journals, SLAS Discovery and SLAS Technology. For more information about SLAS and its jour

Upcoming SLAS Events:

SLAS Building Biology in 3D Symposium

• April 16-17, 2024
• Jupiter, FL, USA

SLAS Europe 2024 Conference and Exhibition

• May 27-29, 2024
• Barcelona, Spain

View the full events calendar